Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

R88-APOBEC3Gm Inhibits the Replication of Both Drug-resistant Strains of HIV-1 and Viruses Produced From Latently Infected Cells.

Wang X, Ao Z, Danappa Jayappa K, Shi B, Kobinger G, Yao X.

Mol Ther Nucleic Acids. 2014 Mar 4;3:e151. doi: 10.1038/mtna.2014.2.

2.

Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.

Ao Z, Yu Z, Wang L, Zheng Y, Yao X.

PLoS One. 2008 Apr 16;3(4):e1995. doi: 10.1371/journal.pone.0001995.

3.

Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages.

Ao Z, Wang X, Bello A, Jayappa KD, Yu Z, Fowke K, He X, Chen X, Li J, Kobinger G, Yao X.

Hum Gene Ther. 2011 Oct;22(10):1225-37. doi: 10.1089/hum.2010.012. Epub 2011 Mar 18.

4.

A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells.

Macías D, Oya R, Saniger L, Martín F, Luque F.

Hum Gene Ther. 2009 Nov;20(11):1259-68. doi: 10.1089/hum.2009.059.

PMID:
19604078
6.

Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.

Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, Ashworth R, Gange S, Quinn TC, Siliciano RF, Persaud D.

J Virol. 2002 Sep;76(18):9481-92.

7.
8.

A unified concept of HIV latency.

Bagasra O.

Expert Opin Biol Ther. 2006 Nov;6(11):1135-49. Review.

PMID:
17049012
9.

The Oncolytic Virus MG1 Targets and Eliminates Cells Latently Infected With HIV-1: Implications for an HIV Cure.

Ranganath N, Sandstrom TS, Burke Schinkel SC, Côté SC, Angel JB.

J Infect Dis. 2018 Feb 14;217(5):721-730. doi: 10.1093/infdis/jix639.

PMID:
29228368
11.

Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.

Chun TW, Justement JS, Moir S, Hallahan CW, Ehler LA, Liu S, McLaughlin M, Dybul M, Mican JM, Fauci AS.

Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):253-8.

12.

Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1.

Arenaccio C, Anticoli S, Manfredi F, Chiozzini C, Olivetta E, Federico M.

Retrovirology. 2015 Oct 26;12:87. doi: 10.1186/s12977-015-0216-y.

13.

Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single-chain variable fragments.

Ho WZ, Lai JP, Bouhamdan M, Duan L, Pomerantz RJ, Starr SE.

AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1573-80.

PMID:
9840290
14.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
15.

Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Donahue DA, Bastarache SM, Sloan RD, Wainberg MA.

J Virol. 2013 Sep;87(17):9620-32. doi: 10.1128/JVI.01165-13. Epub 2013 Jun 26.

16.

Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.

Rong L, Perelson AS.

PLoS Comput Biol. 2009 Oct;5(10):e1000533. doi: 10.1371/journal.pcbi.1000533. Epub 2009 Oct 16.

17.

The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.

Casartelli N, Guivel-Benhassine F, Bouziat R, Brandler S, Schwartz O, Moris A.

J Exp Med. 2010 Jan 18;207(1):39-49. doi: 10.1084/jem.20091933. Epub 2009 Dec 28.

19.

Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.

Sedaghat AR, Siliciano RF, Wilke CO.

BMC Infect Dis. 2008 Jan 2;8:2. doi: 10.1186/1471-2334-8-2.

20.

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.

Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, Richman DD, O'Doherty U, Palmer S, Hecht FM, Hoh R, Barnard RJ, Miller MD, Hazuda DJ, Deeks SG, Sékaly RP, Chomont N.

EBioMedicine. 2015 Jun 27;2(8):874-83. doi: 10.1016/j.ebiom.2015.06.019. eCollection 2015 Aug.

Supplemental Content

Support Center